Works by Eschbach, Ralf S.

Results: 6

Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma.

Published in:

PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0204930

By:

Kazmierczak, Philipp M.;
Burton, Neal C.;
Keinrath, Georg;
Hirner-Eppeneder, Heidrun;
Schneider, Moritz J.;
Eschbach, Ralf S.;
Heimer, Maurice;
Solyanik, Olga;
Todica, Andrei;
Reiser, Maximilian F.;
Ricke, Jens;
Cyran, Clemens C.

Publication type:

Article

Correlation of Perfusion MRI and 18F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation.

Published in:

PLoS ONE, 2015, v. 10, n. 2, p. 1, doi. 10.1371/journal.pone.0115543

By:

Eschbach, Ralf S.;
Fendler, Wolfgang P.;
Kazmierczak, Philipp M.;
Hacker, Marcus;
Rominger, Axel;
Carlsen, Janette;
Hirner-Eppeneder, Heidrun;
Schuster, Jessica;
Moser, Matthias;
Havla, Lukas;
Schneider, Moritz J.;
Ingrisch, Michael;
Spaeth, Lukas;
Reiser, Maximilian F.;
Nikolaou, Konstantin;
Cyran, Clemens C.

Publication type:

Article

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.

Published in:

2018

By:

Kunz, Wolfgang G.;
Eschbach, Ralf S.;
Stahl, Robert;
Kazmierczak, Philipp M.;
Bartenstein, Peter;
Rominger, Axel;
Auernhammer, Christoph J.;
Spitzweg, Christine;
Ricke, Jens;
Cyran, Clemens C.

Publication type:

journal article

18F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.

Published in:

2018

By:

Eschbach, Ralf S.;
Kazmierczak, Philipp M.;
Heimer, Maurice M.;
Todica, Andrei;
Hirner-Eppeneder, Heidrun;
Schneider, Moritz J.;
Keinrath, Georg;
Solyanik, Olga;
Olivier, Jessica;
Kunz, Wolfgang G.;
Reiser, Maximilian F.;
Bartenstein, Peter;
Ricke, Jens;
Cyran, Clemens C.

Publication type:

journal article

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.992316

By:

Eschbach, Ralf S.;
Hofmann, Markus;
Späth, Lukas;
Sheikh, Gabriel T.;
Delker, Astrid;
Lindner, Simon;
Jurkschat, Klaus;
Wängler, Carmen;
Wängler, Björn;
Schirrmacher, Ralf;
Tiling, Reinhold;
Brendel, Matthias;
Wenter, Vera;
Dekorsy, Franziska J.;
Zacherl, Mathias J.;
Todica, Andrei;
Ilhan, Harun;
Grawe, Freba;
Cyran, Clemens C.;
Unterrainer, Marcus

Publication type:

Article

68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.

Published in:

PLoS ONE, 2016, v. 11, n. 12, p. 1, doi. 10.1371/journal.pone.0168248

By:

Kazmierczak, Philipp M.;
Todica, Andrei;
Gildehaus, Franz-Josef;
Hirner-Eppeneder, Heidrun;
Brendel, Matthias;
Eschbach, Ralf S.;
Hellmann, Magdalena;
Nikolaou, Konstantin;
Reiser, Maximilian F.;
Wester, Hans-Jürgen;
Kropf, Saskia;
Rominger, Axel;
Cyran, Clemens C.

Publication type:

Article

Works by Eschbach, Ralf S.

Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma.

Correlation of Perfusion MRI and <sup>18</sup>F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation.

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.

<sup>18</sup>F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [<sup>18</sup>F]SiTATE.

<sup>68</sup>Ga-TRAP-(RGD)<sub>3</sub> Hybrid Imaging for the In Vivo Monitoring of α<sub>v</sub>ß<sub>3</sub>-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.